Retrospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. May 14, 2015; 21(18): 5582-5590
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5582
Table 2 Baseline characteristics for hepatocellular carcinoma patients undergoing transarterial chemoembolization (n = 224)
VariablesValue
Age (yr)53 (23-80)
Sex (M/F)199/25
WBC (× 109/L)6.6 (2.1-24.6)
Neutrophil count (× 109/L)4.2 (0.7-13.6)
Lymphocyte count (× 109/L)1.5 (0.3-4.8)
CRP (mg/L)21.1 (0.2-218.3)
PLT count (× 109/L)182 (23-548)
ALT (U/L)55.6 (8.0-304.0)
AST (U/L)76.3 (20.2-472.6)
Albumin (g/L)38.9 (7.6-79.4)
Total serum bilirubin (mmol/L)18.0 (4.8-222.9)
ALP (IU/L)148.7 (13.0-574.6)
AFP (ng/mL)25828.4 (1.3-1210000.0)
AFU (U/L)43.8 (12.6-992.0)
Diameter of largest lesion (cm)9.2 (1.4-20.0)
Tumor number (solitary/multiple)71/153
Vascular invasion (absent/present)149/75
Child-Pugh grade (A/B)208/16
GPS (0/1/2)99/101/24
Modified GPS (0/1/2)115/85/24
NLR (0/1)108/116
PLR (0/1/2)156/57/11
PI (0/1/2)115/102/7
PNI (0/1)154/70
TNM stage (I/II/IIIa/IIIb/IVa/IVb)44/24/71/52/5/28
CLIP score (0/1/2/3/4/5)19/56/70/43/34/2
BCLC stage (A/B/C)10/124/90
AFP: Alpha-fetoprotein level; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFU: Alpha-L-fucosidase; AST: Aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; CLIP: Cancer of the Liver Italian Program; CRP: C-reactive protein; GPS: Glasgow Prognostic Score; NLR: Neutrophil-lymphocyte ratio; PI: Prognostic Index; PLR: Platelet-lymphocyte ratio; PNI: Prognostic Nutritional Index; TNM: Tumor-node-metastasis; WBC: White blood cell count. Data are presented as mean (range) or n.